Search
19-Nor-5-androstenedione
go.drugbank.com/drugs/DB01443ExperimentalIllicitIt is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports. … 19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo.
Methyl salicylate 2-ethylbutyrate
go.drugbank.com/drugs/DB14130InvestigationalMixtures: Thera Derm Roll OnOlmutinib
go.drugbank.com/drugs/DB13164InvestigationalOlmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.
Ocriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnOcriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
Pyridoxal
go.drugbank.com/drugs/DB00147ExperimentalNutraceuticalThe 4-carboxyaldehyde form of vitamin B 6 which is converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic
Amubarvimab
go.drugbank.com/drugs/DB16493InvestigationalAmubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
cryopreserved human liver cells
go.drugbank.com/drugs/DB05852ExperimentalVesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. … The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation
MLN3897
go.drugbank.com/drugs/DB06505ExperimentalMLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.